A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumours (StrateGIST Frontline) is a phase 3 interventional study registered as NCT07585266, led by GlaxoSmithKline, and recruiting on the registry. Official title: A Phase 3, Randomised, Multicenter, Open-Label Study of Velzatinib (GSK6042981) Versus Imatinib in Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumours (GIST). Planned enrolment is 800 participants (estimated). The study started in 2026-07-27 and primary completion is expected in 2032-08-30. No results have been posted on ClinicalTrials.gov.